Arrowstreet Capital Limited Partnership grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 5.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 395,769 shares of the company’s stock after buying an additional 20,736 shares during the quarter. Arrowstreet Capital Limited Partnership owned 1.39% of Medpace worth $190,044,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Gibbs Wealth Management raised its holdings in shares of Medpace by 210.7% in the 1st quarter. Gibbs Wealth Management now owns 1,221 shares of the company’s stock valued at $586,000 after purchasing an additional 828 shares in the last quarter. Militia Capital Management LLC purchased a new position in Medpace during the first quarter valued at approximately $3,389,000. NewEdge Wealth LLC increased its holdings in Medpace by 1,044.6% during the first quarter. NewEdge Wealth LLC now owns 49,777 shares of the company’s stock valued at $23,902,000 after buying an additional 45,428 shares during the period. Balefire LLC boosted its position in Medpace by 6.1% during the first quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after purchasing an additional 26 shares in the last quarter. Finally, Swiss National Bank increased its position in shares of Medpace by 0.4% during the first quarter. Swiss National Bank now owns 44,480 shares of the company’s stock worth $21,359,000 after purchasing an additional 160 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 20.50% of the company’s stock.
Medpace Stock Down 0.7% MEDP opened at $601.38 on Friday. The company has a market cap of $17.18 billion, a PE ratio of 35.25, a P/E/G ratio of 2.96 and a beta of 1.15. The business has a 50 day moving average price of $492.09 and a two-hundred day moving average price of $494.49. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90.
Medpace (NASDAQ:MEDP – Get Free Report) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same period in the previous year, the firm earned $3.10 EPS. The business’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 17.45 EPS for the current fiscal year.
Key Medpace News Here are the key news stories impacting Medpace this week:
Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article Analyst Ratings Changes Several research firms have recently commented on MEDP. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Royal Bank Of Canada boosted their price objective on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and raised their target price for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Truist Financial upped their price objective on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday. Finally, Robert W. Baird raised their price objective on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday. Two investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $560.92.
Read Our Latest Report on Medpace
Medpace Profile (Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Articles Five stocks we like better than Medpace AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEABN Amro Investment Solutions Has $1.95 Million Stake in Mitsubishi UFJ Financial Group, Inc. $MUFG
NEXT HEADLINE »Arrowstreet Capital Limited Partnership Increases Stock Holdings in HubSpot, Inc. $HUBS
Medpace Holdings demonstrates strong Q2 2026 net new business awards, with a 1.13x net book-to-bill and $3.0B backlog. Oncology bookings are robust, while cardiometabolic awards have declined; management expects mix normalization over the next year. Guidance is lifted on improved RFP trends, biotech funding breadth, and moderated cancellations, supporting growth momentum into 2027.
A strong stock as of late has been Medpace (MEDP - Free Report) . Shares have been marching higher, with the stock up 16.5% over the past month. The stock hit a new 52-week high of $677.9 in the previous session. Medpace has gained 7.9% since the start of the year compared to the -0.1% gain for the Zacks Medical sector and the -1.8% return for the Zacks Medical Services industry.
What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on July 22, 2026, Medpace reported EPS of $4.25 versus consensus estimate of $4.08 while it beat the consensus revenue estimate by 1.12%.
For the current fiscal year, Medpace is expected to post earnings of $17.12 per share on $2.81 in revenues. This represents a 12.04% change in EPS on a 11.02% change in revenues. For the next fiscal year, the company is expected to earn $18.63 per share on $2.92 in revenues. This represents a year-over-year change of 8.8% and 4.07%, respectively.
Valuation MetricsMedpace may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.
Medpace has a Value Score of D. The stock's Growth and Momentum Scores are A and B, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 35.4X current fiscal year EPS estimates, which is a premium to the peer industry average of 16X. On a trailing cash flow basis, the stock currently trades at 35.6X versus its peer group's average of 10X. Additionally, the stock has a PEG ratio of 3.01. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks RankWe also need to consider the stock's Zacks Rank, as this is even more important than the company's VGM Score. Fortunately, Medpace currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Medpace passes the test. Thus, it seems as though Medpace shares could still be poised for more gains ahead.
How Does MEDP Stack Up to the Competition?Shares of MEDP have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is CVS Health Corporation (CVS - Free Report) . CVS has a Zacks Rank of #2 (Buy) and a Value Score of A, a Growth Score of C, and a Momentum Score of B.
Earnings were strong last quarter. CVS Health Corporation beat our consensus estimate by 16.29%, and for the current fiscal year, CVS is expected to post earnings of $7.46 per share on revenue of $409 billion.
Shares of CVS Health Corporation have gained 2.1% over the past month, and currently trade at a forward P/E of 14.33X and a P/CF of 7.18X.
The Medical Services industry is in the top 39% of all the industries we have in our universe, so it looks like there are some nice tailwinds for MEDP and CVS, even beyond their own solid fundamental situation.
The clinical contract research organization reported earnings of $4.25, beating the consensus of $3.97.
The company reported sales of $707.33 million, surpassing the consensus of $687.65 million.
Revenues increased 17.2% year over year, representing a backlog conversion rate of 24.1%.
EBITDA climbed 17.6% to $153.4 million, representing 21.7% of total revenue.
Backlog Continues To GrowMeanwhile, the company’s project backlog grew 4.9% year-over-year to over $3.01 billion. Net new business awards hit $795.7 million for the quarter, generating a healthy net book-to-bill ratio of 1.13x.
CEO August Troendle in the earnings conference call said, “Cancellations were well-behaved and supported a record quarter for net bookings. RFPs were up sequentially and year over year, generating high-quality opportunities.”
“Overall, the environment remains constructive into July, and we are making good progress in positioning the business for 2027,” Troendle further commented.
Medpace Raises Fiscal 2026 GuidanceMedpace on Wednesday raised its fiscal 2026 earnings from $16.68-$17.50 per share to $17.25-$17.95 per share compared to the consensus of $16.97.
The company also increased fiscal 2026 revenue guidance from $2.755 billion-$2.855 billion to $2.805 billion-$2.885 billion compared to the consensus of $2.778 billion.
EBITDA is expected to reach between $618.0 million and $642.0 million.
MEDP Stock Price Activity: Medpace Holdings shares were up 14.24% at $603.31 at the time of publication on Thursday, according to Benzinga Pro data.
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
Medpace Holdings, Inc. (MEDP) Q2 2026 Earnings Call July 23, 2026 9:00 AM EDT
Company Participants
David Ruhe
August Troendle - CEO, President & Chairman
Kevin Brady - CFO & Treasurer
Conference Call Participants
Charles Rhyee - TD Cowen, Research Division
Michael Cherny - Leerink Partners LLC, Research Division
Ann Hynes - Mizuho Securities USA LLC, Research Division
Jailendra Singh - Truist Securities, Inc., Research Division
Christine Rains - William Blair & Company L.L.C., Research Division
David Windley - Jefferies LLC, Research Division
Ryan Halsted - RBC Capital Markets, Research Division
Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division
Justin Bowers - Deutsche Bank AG, Research Division
Presentation
Operator
Good day, ladies and gentlemen, and welcome to the Medpace Second Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to introduce your host for today's conference call, David Ruhe, Medpace's Director of Investor Relations. You may begin.
David Ruhe
Good morning, and thank you for joining Medpace's second quarter 2026 Earnings Conference Call. Also on the call today is our CEO, August Troendle; and our CFO, Kevin Brady. Before we begin, I would like to remind you that our remarks and responses to your questions during this teleconference may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve inherent assumptions with known and unknown risks and uncertainties as well as other important factors that could cause actual results to differ materially from our current expectations. These factors are discussed in our Form 10-K and other filings with the SEC. Please note that we assume no obligation to update forward-looking statements even if estimates change. Accordingly, you should not rely on any of today's forward-looking statements as representing our views as of any date after today.
Medpace Holdings remains a "Buy" as Q2 2026 showed broad metric improvement and an inflection point in growth trajectory. The company's net book-to-Bill ratio rebounded to 1.13x, and backlog conversion rate rose to 24.1%, signaling strong future revenue visibility. Revenue grew 17.2% YoY to $707.3M, with EPS of $4.25 beating expectations; full-year 2026 guidance was raised to $2.805B–$2.885B.
Can Medpace Stock Keep up this Pace?Medpace NASDAQ: MEDP reported double-digit growth in second-quarter revenue and earnings, while management described the business environment as strong and said lower cancellations helped drive record net bookings.
CEO August Troendle said on the company’s second-quarter 2026 earnings call that cancellations were “well-behaved” in the period and supported a record quarter for net bookings. He added that requests for proposals increased both sequentially and year over year, producing what he called “high-quality opportunities.”
Get Medpace alerts:
“Overall, the environment remains constructive into July,” Troendle said. “We are making good progress in positioning the business for 2027.”
Second-Quarter Revenue Rises 17.2% CFO Kevin Brady said Medpace generated second-quarter revenue of $707.3 million, up 17.2% from the year-ago period. Revenue for the first six months of 2026 was $1.41 billion, an increase of 21.7%.
EBITDA for the quarter rose 17.6% to $153.4 million from $130.5 million in the second quarter of 2025. EBITDA margin was 21.7%, compared with 21.6% a year earlier. Year-to-date EBITDA was $302.8 million, up 21.5%, with the EBITDA margin flat at 21.4%.
Brady said the year-to-date margin reflected the impact of higher reimbursable costs, offset primarily by lower employee-related costs.
Net income increased 34.5% to $121.4 million from $90.3 million in the prior-year quarter. Brady attributed the stronger net income growth relative to EBITDA growth primarily to a lower effective tax rate and higher interest income. Diluted earnings per share were $4.25, compared with $3.10 in the second quarter of 2025.
For the first six months of 2026, net income was $245.2 million, up 19.7% from $204.9 million in the comparable prior-year period. Year-to-date diluted EPS was $8.53, compared with $6.79.
Bookings Reach Record Level as Cancellations Improve Net new business awards entering backlog increased 28.2% year over year to $795.7 million, producing a net book-to-bill ratio of 1.13. Ending backlog as of June 30 was approximately $3 billion, up 4.9% from the prior year. Brady said Medpace expects roughly $1.96 billion of backlog to convert to revenue over the next 12 months.
Backlog conversion in the second quarter was 24.1% of beginning backlog. Brady also said Medpace’s top five and top 10 customers represented approximately 31% and 40%, respectively, of revenue over the last 12 months.
In response to analyst questions, Troendle said the improvement in net bookings from the first quarter was driven more by reduced cancellations than by gross bookings. He said cancellations had fallen to a “very good level,” though not an unusually low one.
“Cancellations are always a wild card,” Troendle said, adding that the company has limited ability to predict them. He said Medpace has been careful about what it recognizes in backlog when programs include interim analyses, regulatory decisions or other points that could affect whether a study continues.
Therapeutic Mix Shifts Back Toward Oncology Troendle said recent growth among Medpace’s top customers had been driven “quite a bit” by metabolic work, including large programs within the company’s top five customers. However, he said the mix of new opportunities has shifted in recent quarters.
“Oncology has come back quite a bit in terms of both our award notifications” and bookings, Troendle said. He said oncology represented more than half of overall bookings and award notifications in the second quarter, while cardiometabolic had “dropped off quite a bit” in new award notifications.
Troendle said he expects the company’s therapeutic mix to move back toward historical averages over the next year or so, with oncology regaining a larger position in the mix. He said some of the very large metabolic programs are reducing, and new opportunities in that area are not as large as they were a year ago.
Management also addressed questions about backlog conversion and whether metabolic programs were responsible for a higher burn rate. Troendle said he would “challenge the very premise” that metabolic programs were the primary driver of increased conversion, noting that Medpace often limits backlog recognition beyond interim decision points across many types of programs, including oncology.
Cash Flow, Buybacks and 2026 Guidance Medpace generated $162 million in cash flow from operating activities in the quarter, and Brady said net days sales outstanding were negative 59.6 days. The company ended the quarter with $502.7 million in cash.
During the second quarter, Medpace repurchased approximately 706,000 shares for $294.7 million. As of June 30, the company had $527 million remaining under its share repurchase authorization.
Medpace updated its full-year 2026 guidance. The company now expects:
Total revenue: $2.805 billion to $2.885 billion, representing growth of 10.9% to 14% over 2025 revenue of $2.53 billion. EBITDA: $618 million to $642 million, representing growth of 10.8% to 15.1% compared with 2025 EBITDA of $557.7 million. Net income: $494 million to $514 million. Diluted EPS: $17.25 to $17.95. Brady said the guidance assumes a full-year effective tax rate of 19% to 19.5%, interest income of $21.1 million and no additional share repurchases. The forecast is based on foreign exchange rates as of June 30, 2026.
Management Points to Stronger Funding Environment On the broader market backdrop, Troendle said the environment has strengthened over the last several quarters. He said clients with recent funding are generating more opportunities and moving forward with programs.
Asked about competition and pricing, Troendle said he did not see notable changes in competitive dynamics. He said the profile of opportunities has moved back toward oncology being the largest category, compared with the metabolic drivers seen about a year ago.
Troendle also said the company had implemented changes intended to improve win rates after recognizing that its win rate in 2025 had been lower than in prior years. He declined to provide details on those competitive changes but said they may have influenced the company’s strong win rate in the first quarter.
On labor, Troendle said Medpace is “in a good place,” helped by continued low employee turnover. He said the company expects high-single-digit employee growth this year and suspects that trend will continue next year. Employee growth has been strongest in the U.S., followed by Asia Pacific, including India.
About Medpace (NASDAQ:MEDP)Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Medpace Right Now?Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Medpace (MEDP - Free Report) came out with quarterly earnings of $4.25 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $3.1 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +4.17%. A quarter ago, it was expected that this provider of outsourced clinical development services would post earnings of $3.74 per share when it actually produced earnings of $4.28, delivering a surprise of +14.44%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Medpace, which belongs to the Zacks Medical Services industry, posted revenues of $707.33 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.12%. This compares to year-ago revenues of $603.31 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Medpace shares have lost about 5.3% since the beginning of the year versus the S&P 500's gain of 9.7%.
What's Next for Medpace?While Medpace has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Medpace was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $4.22 on $694.23 million in revenues for the coming quarter and $17.04 on $2.79 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Avantor, Inc. (AVTR - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on July 29.
This company is expected to post quarterly earnings of $0.19 per share in its upcoming report, which represents a year-over-year change of -20.8%. The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level.
Avantor, Inc.'s revenues are expected to be $1.62 billion, down 3.5% from the year-ago quarter.
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Results Revenue for the three months ended June 30, 2026 increased 17.2% to $707.3 million, compared to $603.3 million for the comparable prior-year period. On a constant currency basis, revenue for the second quarter of 2026 increased 17.2% compared to the second quarter of 2025. Backlog as of June 30, 2026 in.
Investors.com will undergo scheduled maintenance from 10:00 PM ET to 2:00 AM ET and some features may be unavailable. We apologize for any inconvenience.
Store
SubscribeSign In
My Subscriptions
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD LiveCustomer Center
My Stock Lists
Email Preferences
Help & Support
Sign Out
Search stocks or keywords
Sections
My IBD
MARKET TREND
STOCK LISTS
STOCK RESEARCH
NEWSECONOMY
VIDEOS & PODCASTS
HOW TO INVESTEDUCATIONAL RESOURCESStoreMy Products
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD Live
Recently Searched
Newly Public Memory-Chip Maker SK Hynix Soars Nearly 14%, Leads 18 To Today's Best Stock Lists
Super Micro Soars Late On Booming Margins, Orders; Dell, HP Enterprise Also Rally
Stock Market Rally Defies Rising Oil, Bond Yields; Chips Lead As Seagate, Micron Make Bullish Moves Medpace Holdings (MEDP) stock surged by double digits late Wednesday, helped by a big bookings beat, rebounding from a poor start to the year. The contract research organization, or CRO, put up a book-to-bill ratio of 1.13x, easily above expectations for 0.95x to 1.01x, according to Leerink Partners analyst Michael Cherny. That means Medpace received more new orders than it…
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Medpace (MEDP - Free Report) Medpace Holdings, Inc. is a global clinical contract research organization (CRO) delivering full-service Phase I-IV drug and device development support, including protocol and project management, regulatory affairs, clinical monitoring, data management/analysis, pharmacovigilance, submission support, and specialized services such as bioanalytical labs and medical imaging. The company is headquartered in Cincinnati, OH, and employs approximately 6,200 people across 46 countries as of fiscal 2025.
MEDP is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. MEDP has a Growth Style Score of A, forecasting year-over-year earnings growth of 11.5% for the current fiscal year.
One analyst revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.00 to $17.04 per share. MEDP also boasts an average earnings surprise of +10%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, MEDP should be on investors' short list.
Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON - Free Report) and Medpace (MEDP - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Right now, Concentra Group is sporting a Zacks Rank of #2 (Buy), while Medpace has a Zacks Rank of #3 (Hold). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that CON has an improving earnings outlook. But this is just one factor that value investors are interested in.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
CON currently has a forward P/E ratio of 20.30, while MEDP has a forward P/E of 31.47. We also note that CON has a PEG ratio of 1.41. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. MEDP currently has a PEG ratio of 2.72.
Another notable valuation metric for CON is its P/B ratio of 9.19. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, MEDP has a P/B of 25.59.
These are just a few of the metrics contributing to CON's Value grade of B and MEDP's Value grade of D.
CON stands above MEDP thanks to its solid earnings outlook, and based on these valuation figures, we also feel that CON is the superior value option right now.
In the latest close session, Medpace (MEDP - Free Report) was down 1.49% at $530.19. The stock trailed the S&P 500, which registered a daily loss of 0.79%. At the same time, the Dow lost 0.26%, and the tech-heavy Nasdaq lost 1.55%.
Shares of the provider of outsourced clinical development services have appreciated by 15.17% over the course of the past month, outperforming the Medical sector's gain of 5.5%, and the S&P 500's gain of 4.28%.
The upcoming earnings release of Medpace will be of great interest to investors. The company's earnings report is expected on July 22, 2026. The company's upcoming EPS is projected at $4.08, signifying a 31.61% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $699.51 million, up 15.95% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.04 per share and revenue of $2.79 billion, indicating changes of +11.52% and +10.32%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Medpace. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Medpace is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Medpace is holding a Forward P/E ratio of 31.59. For comparison, its industry has an average Forward P/E of 15.5, which means Medpace is trading at a premium to the group.
We can additionally observe that MEDP currently boasts a PEG ratio of 2.73. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. MEDP's industry had an average PEG ratio of 1.44 as of yesterday's close.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 109, positioning it in the top 45% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
On July 07, 2026, Medpace Holdings Inc (MEDP) shares fell 3.4% today to a current price of $546.29. The stock has experienced significant volatility, trading wi
Key Takeaways Medpace sees uneven trial demand, with metabolic programs steadier than oncology and cardiovascular.MEDP says awards take three to five quarters to convert, extending the path from pipeline to revenue.Medpace maintained solid EBITDA margins as AI spending is expected to outweigh savings through 2026-2027. Medpace Holdings, Inc. (MEDP - Free Report) offers a focused view of how clinical research organization demand is changing in 2026.
The company’s growth story is not just about trial volume. It also turns on which therapeutic areas are holding up, how quickly awards convert to revenues, and whether technology spending can improve productivity later.
Medpace Shows a Split in Trial DemandDemand across Medpace’s book is becoming more uneven by therapeutic area. Metabolic and GLP-1 programs have historically carried lower cancellation rates, giving that work a stabilizing role in backlog quality and utilization.
Oncology and cardiovascular have been the larger sources of recent cancellations. That matters because both remain important pieces of Medpace’s clinical-development base, and pressure in those areas can weigh on forward visibility even when other categories remain steadier.
The same theme is relevant across the broader clinical services group. IQVIA Holdings Inc. (IQV - Free Report) , which provides clinical research services, healthcare intelligence and technology solutions, is another name investors often watch when trial starts and sponsor spending patterns shift.
MEDP Awards Point to a Longer Conversion CycleMedpace’s early award signals are not translating into immediate revenues. Initial award notifications and win rates have improved, but many awards remain in pre-backlog before moving into active projects.
The timing gap is meaningful. Awards can take three to five quarters to start, which means improved pipeline activity may support later-period growth rather than near-term acceleration.
That delayed conversion cycle helps explain why backlog can support continuity without proving a sharp rebound. Medpace expects roughly $1.9 billion to $1.94 billion of backlog to convert into revenues over the next 12 months, but first-quarter net book-to-bill was 0.88X.
Image Source: Zacks Investment Research
Medpace Margins Benefit From Full-Service FocusMedpace’s full-service model has helped protect profitability through mix changes. First-quarter EBITDA was $149.4 million, and EBITDA margin was 21.1%, nearly in line with 21.2% in the year-ago period.
That stability came despite elevated reimbursed out-of-pocket activity. Pass-throughs were roughly 44% of revenues in the quarter, creating mix noise that can make reported growth and booking comparisons harder to read.
Execution is becoming as important as volume. Improved employee retention, operating discipline and a centralized full-service platform give Medpace tools to defend margins while demand patterns normalize.
Charles River Laboratories International, Inc. (CRL - Free Report) gives investors another angle on outsourced research demand. Its preclinical and drug-development services sit earlier in the development chain, so its trends can complement what Phase I-IV focused companies reveal about clinical activity.
MEDP AI Spending Raises a Near-Term QuestionMedpace’s technology investment adds another layer to the 2026 growth debate. Artificial intelligence spending is expected to exceed savings through 2026-2027, limiting the near-term productivity benefit.
That does not make the spending unimportant. It shows how healthcare-services companies may need to absorb upfront technology costs before automation, analytics or workflow improvements show up in margins.
For investors, the question is timing. AI can support better execution over time, but the current setup points to expense absorption before measurable operating leverage.
Medpace Scores Reflect Growth With RestraintThe bottom line is that Medpace sits in a healthier position than its softer booking signals suggest, but the trend picture still requires patience. Backlog conversion, metabolic exposure and durable margins support the story, while cancellations, longer start times and AI spending keep the near-term setup measured.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). That indicates a more balanced short-term earnings-revision profile rather than a clear positive or negative signal. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Medpace’s Style Scores sharpen that view. Its Growth Score of A points to attractive growth characteristics, while its Momentum Score of C is more neutral and its Value Score of D signals less obvious valuation support. The VGM Score of B suggests the broader style profile remains constructive, but not enough by itself to override the more restrained Zacks Rank #3 signal.
Key Takeaways Medpace's $2.93B backlog supports revenue visibility, with $1.9B-$1.94B expected to convert over 12 months.MEDP's metabolic programs help stabilize backlog as oncology and cardiovascular see higher cancellations.MEDP faces softer proposal activity and a 0.88X book-to-bill ratio, tempering near-term growth signals. Medpace Holdings, Inc. (MEDP - Free Report) has a near-term setup defined less by headline growth and more by the quality of its backlog. Revenue visibility remains meaningful, but booking momentum is not yet sending a clean reacceleration signal.
The company still has several supports, including stable margins, liquidity and metabolic demand. The issue for investors is whether cancellations and softer requests for proposals keep that visibility from turning into faster growth.
Here’s a look at Medpace’s stock performance over the past 12 months.
Image Source: Zacks Investment Research
How Medpace Makes Its Clinical Model WorkMedpace operates as a global, full-service clinical contract research organization supporting Phase I-IV drug and device development. Its services include protocol and project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance, submission support, bioanalytical labs and medical imaging.
The model is centralized and managed as one full-service platform, which helps keep study execution consistent across North America, Europe and Asia. Medpace has particular depth in oncology, metabolic disease, cardiology, central nervous system, antiviral and anti-infective work.
Client mix is another defining feature. Small biopharma accounted for 82% of fiscal 2025 revenues, while mid-sized biopharma represented 13%, leaving MEDP closely tied to emerging and development-stage sponsors.
IQVIA Holdings Inc. (IQV - Free Report) gives investors another large-scale CRO reference point because it provides clinical research services, commercial insights and healthcare intelligence to life sciences customers. Charles River Laboratories International, Inc. (CRL - Free Report) sits in an adjacent contract research area, with drug discovery, non-clinical development and safety testing exposure.
MEDP Backlog Still Supports 2026 RevenueBacklog remains the clearest source of revenue continuity. Medpace ended March 31, 2026, with backlog of $2.93 billion, up 2.9% from the year-ago period.
Management projects roughly $1.9 billion-$1.94 billion of backlog will convert into revenues over the next 12 months. That conversion base gives the company a bridge into 2026 even as net new business awards of $618.4 million produced a net book-to-bill ratio of 0.88X in the first quarter.
The distinction matters. Backlog supports visibility, but a sub-1.0X book-to-bill means awards did not fully replenish quarterly revenues. For now, the backlog points to continuity rather than proof that growth is ready to accelerate.
Take a look at Medpace’s sales multiple over the last five years.
Image Source: Zacks Investment Research
Medpace Finds Stability in Metabolic DemandMetabolic and GLP-1 programs remain an important stabilizer. These programs have historically carried lower cancellation rates than some other tracked therapeutic areas, which supports backlog quality and utilization.
That exposure is valuable because oncology and cardiovascular programs have been more cancellation-prone. In the first quarter of 2026, metabolic revenues reached $237.6 million, exceeding oncology revenues of $201.2 million and making metabolic the largest disclosed therapeutic area by revenue.
The opportunity is not without limits. New metabolic opportunities could face saturation or price sensitivity, but durable in-flight work still helps MEDP absorb pressure elsewhere in the portfolio.
MEDP Faces the Drag From CancellationsCancellations remain the main offset to the backlog story. First-quarter cancellations reached their highest level in more than a year, with oncology and cardiovascular programs the largest contributors.
The demand funnel also looks uneven. Requests for proposals declined sequentially and year over year, while the first-quarter book-to-bill ratio stayed below 1.0X.
Initial award notifications and win rates were stronger, which helps the pipeline narrative. Still, many awards remain in pre-backlog, and typical lags of three to five quarters before program starts limit the immediate revenue benefit.
Medpace Signals Matter for Patient InvestorsThe bottom line is that MEDP offers a balanced signal set. Backlog conversion, stable profitability and metabolic exposure support patience, but cancellations, softer proposal activity and delayed program starts keep the near-term outlook measured.
The stock currently carries a Zacks Rank #3 (Hold), which points to more balanced short-term earnings estimate picture. Its Style Scores show a Growth Score of A, Value Score of D, Momentum Score of C and VGM Score of B. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
That mix fits the current debate. The Growth Score of A and VGM Score of B point to attractive growth traits and a favorable combined style profile, while the Value Score of D suggests valuation support is less clear. For investors, MEDP’s next signal is likely to come from whether backlog quality and awards can outpace cancellations without pressuring margins.
Medpace (MEDP - Free Report) closed the most recent trading day at $543.57, moving +2.64% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.22%. At the same time, the Dow lost 0.03%, and the tech-heavy Nasdaq lost 0.66%.
Shares of the provider of outsourced clinical development services witnessed a gain of 18.85% over the previous month, beating the performance of the Medical sector with its gain of 6.47%, and the S&P 500's loss of 1.21%.
Market participants will be closely following the financial results of Medpace in its upcoming release. The company plans to announce its earnings on July 22, 2026. In that report, analysts expect Medpace to post earnings of $4.08 per share. This would mark year-over-year growth of 31.61%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $678.51 million, up 12.47% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.04 per share and revenue of $2.79 billion, indicating changes of +11.52% and +10.32%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Medpace. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. At present, Medpace boasts a Zacks Rank of #3 (Hold).
Investors should also note Medpace's current valuation metrics, including its Forward P/E ratio of 31.08. This denotes a premium relative to the industry average Forward P/E of 15.95.
Also, we should mention that MEDP has a PEG ratio of 2.69. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical Services industry was having an average PEG ratio of 1.39.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Investors looking for stocks in the Medical Services sector might want to consider either Concentra Group (CON) or Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
In the latest close session, Medpace (MEDP - Free Report) was up +1.4% at $519.96. The stock outpaced the S&P 500's daily loss of 0.01%. On the other hand, the Dow registered a gain of 0.14%, and the technology-centric Nasdaq decreased by 0.46%.
Shares of the provider of outsourced clinical development services have appreciated by 19.81% over the course of the past month, outperforming the Medical sector's gain of 2.92%, and the S&P 500's loss of 1.4%.
The investment community will be closely monitoring the performance of Medpace in its forthcoming earnings report. The company is scheduled to release its earnings on July 22, 2026. It is anticipated that the company will report an EPS of $4.08, marking a 31.61% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $678.51 million, reflecting a 12.47% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.04 per share and a revenue of $2.79 billion, signifying shifts of +11.52% and +10.32%, respectively, from the last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medpace. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Right now, Medpace possesses a Zacks Rank of #2 (Buy).
Looking at its valuation, Medpace is holding a Forward P/E ratio of 30.09. This valuation marks a premium compared to its industry average Forward P/E of 15.24.
Meanwhile, MEDP's PEG ratio is currently 2.6. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical Services stocks are, on average, holding a PEG ratio of 1.4 based on yesterday's closing prices.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
On June 23, 2026, Medpace Holdings Inc MEDP shares rose 3.9% today, closing at $473.53. The stock has experienced a 52-week range of $305.69 to $628.92, reflecting significant volatility over the past year.
GF Value™ verdict: The current price is $473.53, which is 5.8% below the GF Value™ of $502.42.GF Score™: Medpace has a strong GF Score™ of 98/100, indicating robust fundamentals across various dimensions.Most notable signal: The momentum rank is 8/10, suggesting positive price movement trends. Is MEDP Overvalued or Undervalued? Based on the GF Value™ analysis, Medpace Holdings Inc MEDP is considered undervalued at its current price of $473.53, which reflects a 5.8% downside from the intrinsic value estimated at $502.42. This margin of safety suggests a potential buying opportunity for investors willing to accept the inherent risks associated with market fluctuations. The GF Valuation label indicates that the stock is fairly valued, which means that while it may present an opportunity, investors should remain cautious about external market pressures and overall economic conditions. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
How Does MEDP's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 29.8x 31.4x Forward P/E 27.9x N/A The current P/E ratio of 29.8x is 5% below its 5-year median P/E of 31.4x, indicating that the stock is trading below its historical valuation levels. This P/E analysis aligns with the GF Value™ verdict, supporting the notion that MEDP is undervalued and may present a favorable investment opportunity, provided that other financial metrics continue to perform well.
What Does MEDP's GF Score™ Tell Us? Metric Rating GF Score™ 98 Financial Strength 6/10 Profitability 10/10 Growth 10/10 Valuation 10/10 Momentum 8/10 Medpace's high GF Score™ of 98/100 emphasizes its strong fundamentals, particularly in Profitability and Growth, both rated 10/10. This suggests a solid operational performance and potential for future expansion. However, the Financial Strength rating of 6/10 indicates some caution, as it may suggest a moderate level of risk in terms of financial stability. Overall, the strong scores in Profitability, Growth, and Valuation highlight the company’s robust potential, although the financial strength aspect warrants closer scrutiny.
What Are Insiders Doing with MEDP Stock? In the last three months, Medpace insiders sold a total of $7.4 million in shares, indicating a lack of buying activity during this period. This pattern may suggest that insiders are not currently optimistic about the stock's short-term performance, which could point towards caution for outside investors. However, it is important to note that insider selling does not always indicate negative sentiment, as it may also be a strategy for personal financial management or tax purposes.
What This Means for Investors Based on the analysis of GF Value™, Medpace Holdings Inc MEDP is currently undervalued, presenting a potential opportunity for investors looking for stocks with solid fundamentals and growth potential. Nonetheless, caution is advised due to the recent insider selling and market volatility.
For the complete analysis, visit the Medpace Holdings Inc MEDP stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is MEDP's GF Score™?
Medpace's GF Score™ is 98/100, indicating strong fundamentals and a high likelihood of generating long-term returns based on historical data.
Is MEDP overvalued or undervalued?
MEDP is currently considered undervalued, with a GF Value™ of $502.42 compared to its current price of $473.53.
What is MEDP's P/E ratio?
MEDP's P/E ratio (TTM) is 29.8x, which is below its 5-year median P/E of 31.4x, indicating that the stock is trading at a lower valuation compared to its historical averages.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2026 financial results after the market close on Wednesday, July 22, 2026. The Company will host a conference call the following morning, Thursday, July 23, 2026, at 9:00 a.m. ET to discuss these results.
To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.
To access the conference call via webcast, visit the “Investors” section of Medpace’s website at investor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
A supplemental slide presentation will also be available at the “Investors” section of Medpace’s website prior to the start of the call.
About Medpace
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,300 people across 46 countries as of March 31, 2026.
Medpace (MEDP - Free Report) closed the most recent trading day at $461.60, moving -1.26% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.57%. Meanwhile, the Dow experienced a rise of 0.64%, and the technology-dominated Nasdaq saw a decrease of 1.15%.
The provider of outsourced clinical development services's stock has climbed by 11.13% in the past month, exceeding the Medical sector's gain of 4.28% and the S&P 500's gain of 2.14%.
The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company's earnings per share (EPS) are projected to be $4.08, reflecting a 31.61% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $678.51 million, up 12.47% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $17.04 per share and a revenue of $2.79 billion, indicating changes of +11.52% and +10.32%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Medpace. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Medpace is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Medpace's current valuation metrics, including its Forward P/E ratio of 27.44. For comparison, its industry has an average Forward P/E of 15.69, which means Medpace is trading at a premium to the group.
Also, we should mention that MEDP has a PEG ratio of 2.37. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical Services industry had an average PEG ratio of 1.44 as trading concluded yesterday.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 109, putting it in the top 45% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
New York, New York--(Newsfile Corp. - June 5, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Medpace Holdings, Inc. (NASDAQ: MEDP) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Medpace securities between April 22, 2025 and February 9, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/MEDP.
Medpace Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:
Medpace's public statements regarding its expected book-to-bill ratio for the fourth quarter and second half of fiscal year 2025 lacked a reasonable basis; Defendants repeatedly portrayed an overly optimistic book-to-bill ratio of approximately 1.15 during earnings calls and other public communications, despite contrary internal information; and as a result, Defendants' statements about the Company's business, operations, and financial prospects were materially false and misleading at all relevant times.What's Next for Medpace Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/MEDP, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Medpace you have until June 5, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Medpace Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Medpace Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294775
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - June 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO: To join the Medpace class action, go to https://rosenlegal.com/submit-form/?case_id=58453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 8, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or concealed material adverse facts concerning the true state of Medpace's backlog cancellation rate. In fact, defendants continuously touted "well behaved" cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Medpace class action, go to https://rosenlegal.com/submit-form/?case_id=58453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300348
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026. Medpace describes itself as a “clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.”
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.
The Allegations: Rosen Law Firm is Investigating the Allegations that Medpace Holdings, Inc. (NASDAQ: MEDP) Misled Investors Regarding its Business Operations.
According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or concealed material adverse facts concerning the true state of Medpace’s backlog cancellation rate. In fact, defendants continuously touted “well behaved” cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio. When the true details entered the market, the lawsuit claims that investors suffered damages.
What Now: You may be eligible to participate in the class action against Medpace Holdings, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by June 8, 2026. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
, /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP).
IF YOU SUFFERED A LOSS ON YOUR MEDPACE INVESTMENTS, CLICK HERE BEFORE JUNE 8, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT
What Is The Lawsuit About?
The complaint filed alleges that, between April 22, 2025 and February 9, 2026, Defendants: (1) consistently oversold the Company's projected book-to-bill ratio for fourth quarter 2025; (2) knew or recklessly disregarded the impact that cancellations have on the Company's book-to-bill ratio; (3) frequently claimed that the projection of a 1.15 book-to-bill ratio for fourth quarter 2025 was reasonable and achievable and that cancellations were not a sign of a weak business environment; (4) reassured investors that the Company was not concerned about the lack of diversity in its pre-backlog; (5) stated that, despite the uptick in metabolic growth, the Company's upside was broad-based and not isolated to any handful of studies; and (6) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.
, /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, all dates inclusive (the "Class Period"), have until this Monday, June 8, 2026 to seek appointment as lead plaintiff of the Medpace class action lawsuit. Captioned Durbin v. Medpace Holdings Inc., No. 26-cv-00346 (S.D. Ohio), the Medpace class action lawsuit charges Medpace as well as certain of Medpace's top executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Medpace class action lawsuit, please provide your information here:
You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].
CASE ALLEGATIONS: Medpace is a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.
The Medpace class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Medpace consistently oversold Medpace's projected book-to-bill ratio for fourth quarter 2025; (ii) Medpace knew or recklessly disregarded the impact that cancellations have on Medpace's book-to-bill ratio; (iii) Medpace frequently claimed that the projection of a 1.15 book-to-bill ratio for fourth quarter 2025 was reasonable and achievable and that cancellations were not a sign of a weak business environment; (iv) Medpace reassured investors that Medpace was not concerned about the lack of diversity in its pre-backlog; and (v) Medpace management stated that, despite the uptick in metabolic growth, Medpace's upside was broad-based and not isolated to any handful of studies.
The Medpace class action lawsuit further alleges that on February 9, 2026, Medpace released fourth quarter 2025 earnings results revealing a book-to-bill ratio of 1.04, well below Medpace's guidance. On this news, the price of Medpace common stock fell nearly 16%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Medpace common stock during the Class Period to seek appointment as lead plaintiff in the Medpace class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Medpace class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Medpace class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Medpace class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
New York, New York--(Newsfile Corp. - June 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO: To join the Medpace class action, go to https://rosenlegal.com/submit-form/?case_id=58453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 8, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or concealed material adverse facts concerning the true state of Medpace's backlog cancellation rate. In fact, defendants continuously touted "well behaved" cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Medpace class action, go to https://rosenlegal.com/submit-form/?case_id=58453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300351
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Medpace between April 22, 2025 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - June 7, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP) and reminds investors of the June 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the true state of Medpace's backlog cancellation rate. Defendants continuously touted "well behaved" cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio.
On February 9, 2026, Medpace issued a press release announcing the Company's fourth quarter 2025 book-to-bill ratio of 1.04, well below the guidance of 1. 15. Following this news, the price of Medpace's common stock declined dramatically. From a closing market price of $530.35 per share on February 9, 2026, Medpace's common stock price fell to $446. 05 per share on February 10, 2026, a decline of more than 15.9%.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Medpace's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Medpace class action, go to www.faruqilaw.com/MEDP or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300334
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - June 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO: To join the Medpace class action, go to https://rosenlegal.com/submit-form/?case_id=58453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 8, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or concealed material adverse facts concerning the true state of Medpace's backlog cancellation rate. In fact, defendants continuously touted "well behaved" cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Medpace class action, go to https://rosenlegal.com/submit-form/?case_id=58453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300352
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”), of the important June 8, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO: To join the Medpace class action, go to https://rosenlegal.com/submit-form/?case_id=58453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 8, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or concealed material adverse facts concerning the true state of Medpace’s backlog cancellation rate. In fact, defendants continuously touted “well behaved” cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Medpace class action, go to https://rosenlegal.com/submit-form/?case_id=58453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
San Diego, California--(Newsfile Corp. - June 8, 2026) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, all dates inclusive (the "Class Period"), have until today, Monday, June 8, 2026 to seek appointment as lead plaintiff of the Medpace class action lawsuit. Captioned Durbin v. Medpace Holdings Inc., No. 26-cv-00346 (S.D. Ohio), the Medpace class action lawsuit charges Medpace as well as certain of Medpace's top executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Medpace class action lawsuit, please provide your information here:
You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].
CASE ALLEGATIONS: Medpace is a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.
The Medpace class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Medpace consistently oversold Medpace's projected book-to-bill ratio for fourth quarter 2025; (ii) Medpace knew or recklessly disregarded the impact that cancellations have on Medpace's book-to-bill ratio; (iii) Medpace frequently claimed that the projection of a 1.15 book-to-bill ratio for fourth quarter 2025 was reasonable and achievable and that cancellations were not a sign of a weak business environment; (iv) Medpace reassured investors that Medpace was not concerned about the lack of diversity in its pre-backlog; and (v) Medpace management stated that, despite the uptick in metabolic growth, Medpace's upside was broad-based and not isolated to any handful of studies.
The Medpace class action lawsuit further alleges that on February 9, 2026, Medpace released fourth quarter 2025 earnings results revealing a book-to-bill ratio of 1.04, well below Medpace's guidance. On this news, the price of Medpace common stock fell nearly 16%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Medpace common stock during the Class Period to seek appointment as lead plaintiff in the Medpace class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Medpace class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Medpace class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Medpace class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors - $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever - $7.2 billion - in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Medpace between April 22, 2025 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) and reminds investors of the June 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the true state of Medpace's backlog cancellation rate. Defendants continuously touted "well behaved" cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio.
On February 9, 2026, Medpace issued a press release announcing the Company's fourth quarter 2025 book-to-bill ratio of 1.04, well below the guidance of 1.15. Following this news, the price of Medpace's common stock declined dramatically. From a closing market price of $530.35 per share on February 9, 2026, Medpace's common stock price fell to $446.05 per share on February 10, 2026, a decline of more than 15.9%.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Medpace’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Medpace class action, go to www.faruqilaw.com/MEDP or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. (âMedpaceâ or t
RIDGEWOOD, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- RIDGEWOOD, N.J., June 8, 2026 (GLOBE NEWSWIRE) -- Safirstein Law LLC announces that a class action lawsuit has been filed on behalf of shareholders against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ:MEDP).
New York, New York--(Newsfile Corp. - June 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO: To join the Medpace class action, go to https://rosenlegal.com/submit-form/?case_id=58453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 8, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or concealed material adverse facts concerning the true state of Medpace's backlog cancellation rate. In fact, defendants continuously touted "well behaved" cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Medpace class action, go to https://rosenlegal.com/submit-form/?case_id=58453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300515
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Medpace between April 22, 2025 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) and reminds investors of the June 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the true state of Medpace's backlog cancellation rate. Defendants continuously touted "well behaved" cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio.
On February 9, 2026, Medpace issued a press release announcing the Company's fourth quarter 2025 book-to-bill ratio of 1.04, well below the guidance of 1. 15. Following this news, the price of Medpace's common stock declined dramatically. From a closing market price of $530.35 per share on February 9, 2026, Medpace's common stock price fell to $446.05 per share on February 10, 2026, a decline of more than 15.9%.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Medpace’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Medpace class action, go to www.faruqilaw.com/MEDP or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
, /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Medpace Holdings, Inc. (NASDAQ: MEDP) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Medpace securities between April 22, 2025 and February 9, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/MEDP.
Medpace Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:
Medpace's public statements regarding its expected book-to-bill ratio for the fourth quarter and second half of fiscal year 2025 lacked a reasonable basis; Defendants repeatedly portrayed an overly optimistic book-to-bill ratio of approximately 1.15 during earnings calls and other public communications, despite contrary internal information; and as a result, Defendants' statements about the Company's business, operations, and financial prospects were materially false and misleading at all relevant times. What's Next for Medpace Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/MEDP. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Medpace you have until June 8, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Medpace Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Medpace Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.
Medpace (MEDP - Free Report) closed at $466.79 in the latest trading session, marking a +1.94% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.26%. Meanwhile, the Dow experienced a rise of 0.17%, and the technology-dominated Nasdaq saw a decrease of 0.97%.
Prior to today's trading, shares of the provider of outsourced clinical development services had gained 9.73% outpaced the Medical sector's gain of 3.5% and the S&P 500's gain of 0.23%.
Analysts and investors alike will be keeping a close eye on the performance of Medpace in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $4.08, marking a 31.61% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $678.51 million, showing a 12.47% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.04 per share and a revenue of $2.79 billion, signifying shifts of +11.52% and +10.32%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Medpace. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Currently, Medpace is carrying a Zacks Rank of #3 (Hold).
Investors should also note Medpace's current valuation metrics, including its Forward P/E ratio of 26.87. This denotes a premium relative to the industry average Forward P/E of 15.47.
We can additionally observe that MEDP currently boasts a PEG ratio of 2.32. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical Services industry was having an average PEG ratio of 1.44.
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 112, finds itself in the top 46% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Investors looking for stocks in the Medical Services sector might want to consider either Concentra Group (CON - Free Report) or Medpace (MEDP - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Right now, Concentra Group is sporting a Zacks Rank of #2 (Buy), while Medpace has a Zacks Rank of #3 (Hold). Investors should feel comfortable knowing that CON likely has seen a stronger improvement to its earnings outlook than MEDP has recently. However, value investors will care about much more than just this.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
CON currently has a forward P/E ratio of 17.80, while MEDP has a forward P/E of 27.88. We also note that CON has a PEG ratio of 1.24. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. MEDP currently has a PEG ratio of 2.41.
Another notable valuation metric for CON is its P/B ratio of 8.1. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, MEDP has a P/B of 22.68.
These are just a few of the metrics contributing to CON's Value grade of B and MEDP's Value grade of D.
CON is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that CON is likely the superior value option right now.
